Table 2.
Male | Female | |||||||
---|---|---|---|---|---|---|---|---|
Site/Lesion | Vehicle control | 21 μg/kg (adjusted dose 15 μg/kg/d) | 70 μg/kg(adjusted dose 50 μg/kg/d) | 210 μg/kg (adjusted dose 150 μg/kg/d) | Vehicle control | 21 μg/kg (adjusted dose 15 μg/kg/d) | 70 μg/kg (adjusted dose 50 μg/kg/d) | 210 μg/kg (adjusted dose 150 μg/kg/d) |
Number examined | 50 | 51 | 51 | 50 | 50 | 51 | 50 | 50 |
Kidney tubule | ||||||||
Adenoma, solitary | 1 | 1 | 5 | 10 | 0 | 0 | 1 | 3 |
Adenoma, multiple | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
Carcinoma, solitary | 0 | 0 | 12 | 20 | 0 | 0 | 1 | 3 |
Carcinoma, bilateral/multiple | 0 | 0 | 4 | 10 | 0 | 0 | 0 | 0 |
Renal tubule cell adenomas and carcinoma combined | 1 | 1 | 22 | 40 | 0 | 0 | 2 | 8 |
Metastatic renal carcinoma (all sites) | 0 | 0 | 4 | 13 | 0 | 0 | 1 | 0 |
Source: Summarized from results reported in the NTP (1989) rat study.